Key Segmentation
By Molecule Type
-
Monoclonal Antibodies
-
Proteins and Peptides
-
Vaccines
-
Cell and Gene Therapy Products
By Test Type
-
Pharmacokinetics
-
Immunogenicity
-
Cell-Based Assays
-
Others
By Technology
-
Ligand Binding Assays
-
Liquid Chromatography-Mass Spectrometry
-
Cell-Based Assays
-
PCR
By End User
-
Pharmaceutical Companies
-
Biotechnology Companies
-
Contract Research Organizations
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Charles River Laboratories International, Inc., Laboratory Corporation of America Holdings (Labcorp), Thermo Fisher Scientific Inc., Eurofins Scientific SE, SGS SA, WuXi AppTec Co., Ltd., ICON plc and Frontage Laboratories, Inc.
Key opportunities include specialized testing for cell and gene therapy and bispecific antibodies, hybrid ligand binding and mass spectrometry platforms, and new capacity in Asia Pacific and the Middle East.
The major growth factor is the expanding pipeline of biologic drugs together with outsourcing of laboratory work by drug developers.
By Molecule Type, the Monoclonal Antibodies segment dominated the market in 2025 with an estimated 43.00% share, supported by the large pipeline of antibody drugs and biosimilars.
North America dominated the market with a share of 46.00% in 2025, driven by the concentration of drug developers, the largest biologics pipeline and a deep network of contract laboratories.
